Literature DB >> 16823944

Scale up of proteoliposome derived Cochleate production.

Caridad Zayas1, Gustavo Bracho, Miriam Lastre, Domingo González, Danay Gil, Reinaldo Acevedo, Judith del Campo, Carlos Taboada, Rosa L Solís, Ramón Barberá, Oliver Pérez.   

Abstract

Cochleate are highly stable structures with promising immunological features. Cochleate structures are usually obtaining from commercial lipids. Proteoliposome derived Cochleate are derived from an outer membrane vesicles of Neisseria meningitidis B. Previously, we obtained Cochleates using dialysis procedures. In order to increase the production process, we used a crossflow system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The raw material and solutions used in the production process are already approved for human application. This work demonstrates that CFS is very efficient process to obtain Cochleate structures with a yield of more than 80% and the immunogenicity comparable to that obtained by dialysis membrane.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823944     DOI: 10.1016/j.vaccine.2005.01.139

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.

Authors:  O Pérez; A Batista-Duharte; E González; C Zayas; J Balboa; M Cuello; O Cabrera; M Lastre; V E J C Schijns
Journal:  Braz J Med Biol Res       Date:  2012-04-26       Impact factor: 2.590

2.  Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B.

Authors:  Caridad Zayas; Domingo González; Reinaldo Acevedo; Judith del Campo; Miriam Lastre; Elizabeth González; Belkis Romeu; Maribel Cuello; Julio Balboa; Osmir Cabrera; Luisa Guilherme; Oliver Pérez
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

3.  AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.

Authors:  Gustavo Bracho; Caridad Zayas; Lina Wang; Ross Coppel; Oliver Pérez; Nikolai Petrovsky
Journal:  Malar J       Date:  2009-02-27       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.